Publications by authors named "Bruce Randazzo"

Claim this Profile
I
Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trial.
Richard B Warren, Adam Reich, Andrzej Kaszuba, Waldemar Placek, Christopher E M Griffiths, Bruce Randazzo

Br J Dermatol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study.
Andrew Blauvelt, April W Armstrong, Richard G Langley, Kurt Gebauer, Diamant Thaçi, Bruce Randazzo

J Dermatolog Treat· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2.
Luis Puig, Jashin J Wu, Melinda J Gooderham, Yin You, Yaung-Kaung Shen, Bruce Randazzo

J Dermatolog Treat· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extrapolating Pharmacodynamic Effects From Adults to Pediatrics: A Case Study of Ustekinumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis.
Wangda Zhou, Chuanpu Hu, Yaowei Zhu, Bruce Randazzo, Michael Song

Clin Pharmacol Ther· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials.
Kristian Reich, Christopher E M Griffiths, Kenneth B Gordon, Kim A Papp, Michael Song, Bruce Randazzo

J Am Acad Dermatol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
Kristian Reich, April W Armstrong, Richard G Langley, Susan Flavin, Bruce Randazzo

Lancet· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity of Guselkumab Is Not Clinically Relevant in Patients with Moderate-to-Severe Plaque Psoriasis.
Yaowei Zhu, Joseph C Marini, Michael Song, Bruce Randazzo, Yaung-Kaung Shen

J Invest Dermatol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comprehensive evaluation of exposure-response relationships in clinical trials: application to support guselkumab dose selection for patients with psoriasis.
Chuanpu Hu, Zhenling Yao, Yang Chen, Bruce Randazzo, Liping Zhang

J Pharmacokinet Pharmacodyn· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.
Christopher E M Griffiths, Kim A Papp, Alexa B Kimball, Bruce Randazzo, Michael Song

J Drugs Dermatol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Toreforant, a Selective Histamine H4 Receptor Antagonist, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results from a Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Trial.
Ellen Frankel, Michael Song, Shu Li, Jingzhi Jiang, Robin L Thurmond, Bruce Randazzo

J Drugs Dermatol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.
Peter Foley, Kenneth Gordon, Christopher E M Griffiths, Yasmine Wasfi, Bruce Randazzo

JAMA Dermatol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetic Modeling of Guselkumab, a Human IgG1λ Monoclonal Antibody Targeting IL-23, in Patients with Moderate to Severe Plaque Psoriasis.
Zhenling Yao, Chuanpu Hu, Yaowei Zhu, Zhenhua Xu, Bruce Randazzo

J Clin Pharmacol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvement in latent variable indirect response modeling of multiple categorical clinical endpoints: application to modeling of guselkumab treatment effects in psoriatic patients.
Chuanpu Hu, Bruce Randazzo, Amarnath Sharma, Honghui Zhou

J Pharmacokinet Pharmacodyn· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.
Andrew Blauvelt, Kim A Papp, Christopher E M Griffiths, Bruce Randazzo, Yasmine Wasfi

J Am Acad Dermatol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
Kristian Reich, April W Armstrong, Peter Foley, Michael Song, Yasmine Wasfi, Bruce Randazzo

J Am Acad Dermatol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HLA-C*06:02 Allele and Response to IL-12/23 Inhibition: Results from the Ustekinumab Phase 3 Psoriasis Program.
Katherine Li, C Chris Huang, Bruce Randazzo, Shu Li, Philippe Szapary

J Invest Dermatol· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2).
Arthur Kavanaugh, Lluis Puig, Alice B Gottlieb, Christopher Ritchlin, Yin You, Bruce Randazzo

Ann Rheum Dis· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study.
Ian Landells, Colleen Marano, Ming-Chun Hsu, Shu Li, Yaowei Zhu, Bruce Randazzo

J Am Acad Dermatol· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
Kenneth B Gordon, Kristina Callis Duffin, Robert Bissonnette, Jörg C Prinz, Yasmine Wasfi, Bruce Randazzo

N Engl J Med· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of subcutaneous methylnaltrexone in the treatment of opioid-induced constipation: a responder post hoc analysis.
Edward Michna, Arnold J Weil, Marc Duerden, Seth Schulman, Wenjin Wang, Bruce Randazzo

Pain Med· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study.
Edward Michna, E Richard Blonsky, Seth Schulman, Evan Tzanis, Amy Manley, Bruce Randazzo

J Pain· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of methylnaltrexone in shortening the duration of postoperative ileus following segmental colectomy: results of two randomized, placebo-controlled phase 3 trials.
Chang Sik Yu, Ho-Kyung Chun, Nancy Stambler, Jennifer Carpenito, Seth Schulman, Bruce Randazzo

Dis Colon Rectum· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of subcutaneous methylnaltrexone on patient-reported constipation symptoms.
Shrividya S Iyer, Bruce P Randazzo, Evan L Tzanis, Seth L Schulman, Haiying Zhang

Value Health· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis